Last updated: February 19, 2026
DARZALEX (daratumumab and hyaluronidase-fich) is a CD38-directed cytotoxic agent approved for the treatment of multiple myeloma. Its market trajectory is defined by a strong and growing sales performance, driven by expanding indications, global market penetration, and strategic pricing.
What is DARZALEX's Current Market Position?
DARZALEX has established itself as a leading therapy in the multiple myeloma landscape. The drug's efficacy in both frontline and relapsed/refractory settings, coupled with convenient subcutaneous administration, underpins its commercial success. J&J's Janssen Pharmaceutical Companies, the developer, reported net sales of DARZALEX of \$7.2 billion for 2022, representing a 16% increase over 2021. This growth rate indicates sustained demand and market share gains against competing therapies [1].
Key Market Drivers:
- Clinical Efficacy: DARZALEX has demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) across various lines of therapy in multiple myeloma [2]. This robust clinical profile supports its adoption by oncologists.
- Expanding Indications: Regulatory approvals for new indications, including its use in combination regimens for newly diagnosed multiple myeloma (NDMM) patients, have broadened the eligible patient population and driven increased utilization [3].
- Subcutaneous Formulation: The development and approval of a subcutaneous formulation (DARZALEX FASPRO) have enhanced patient convenience and potentially reduced administration time and healthcare resource utilization compared to its intravenous counterpart [4]. This formulation change has been a significant factor in its continued market penetration.
- Global Market Access: Janssen has prioritized global market access for DARZALEX, leading to its availability in key pharmaceutical markets worldwide. This broad geographic reach contributes substantially to its overall sales figures.
- Competitive Landscape: While the multiple myeloma market has several therapeutic options, including other monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs, DARZALEX's differentiated mechanism of action and strong clinical data have allowed it to carve out a significant market segment.
What is DARZALEX's Financial Performance?
DARZALEX's financial performance has been a consistent driver of growth for Johnson & Johnson. Its sales trajectory exhibits a strong upward trend, reflecting its increasing market penetration and the premium pricing typically associated with novel biologic therapies.
Sales History and Projections:
- 2020 Sales: \$4.03 billion [5]
- 2021 Sales: \$6.07 billion [5]
- 2022 Sales: \$7.2 billion [1]
- Projected 2023 Sales: Analysts project continued growth, with some estimates placing 2023 sales above \$8 billion, driven by ongoing market penetration and the expansion of its use in earlier lines of therapy [6].
The drug's financial trajectory is supported by its robust clinical trial data, which has led to multiple label expansions and preferential formulary placements by payers. The average wholesale price (AWP) for DARZALEX varies based on dosage and administration route, but it generally reflects a high-value therapeutic for a chronic and serious disease [7].
What are the Patent Expirations and Market Exclusivity for DARZALEX?
Understanding patent exclusivity is critical for forecasting future market competition and potential generic or biosimilar entry. DARZALEX, as a biologic drug, is protected by a complex web of patents covering its active ingredient (daratumumab), formulations, methods of use, and manufacturing processes.
Key Patent Considerations:
- Composition of Matter Patents: The primary patents protecting the daratumumab molecule itself are nearing expiration. For instance, U.S. Patent No. 8,894,990, a key composition of matter patent, is expected to expire in 2026 [8].
- Formulation Patents: Patents related to the subcutaneous formulation (DARZALEX FASPRO) provide additional layers of protection. These patents have varying expiration dates, extending exclusivity beyond the composition of matter patents.
- Method of Use Patents: Patents covering specific therapeutic uses, such as its use in combination with other agents or for specific patient populations, can also extend market exclusivity.
- Data Exclusivity: In addition to patent protection, biologic drugs are granted a period of data exclusivity by regulatory agencies (e.g., 12 years in the U.S. for a new biologic approved after 2003). This prevents biosimilar applicants from relying on the innovator's clinical trial data during this period [9].
The expiration of core composition of matter patents in the mid-to-late 2020s will pave the way for potential biosimilar competition. However, the intricate patent landscape, including formulation and method-of-use patents, may present challenges for biosimilar developers. The timeline for biosimilar entry will depend on the specific patents challenged and the legal outcomes of any patent litigation [10].
What is the Competitive Landscape for DARZALEX?
The multiple myeloma market is highly competitive, with a continuous influx of new therapies and treatment paradigms. DARZALEX faces competition from various drug classes and direct competitors targeting CD38 or other crucial pathways in multiple myeloma.
Major Competitors:
- Other CD38 Monoclonal Antibodies:
- Isatuximab (SARCLISA): Developed by Sanofi, isatuximab is also a CD38-targeting antibody. While approved for relapsed/refractory multiple myeloma, its clinical differentiation and market share against DARZALEX are areas of ongoing assessment [11].
- CAR T-cell Therapies:
- Abecma (idecabtagene vicleucel): Developed by Bristol Myers Squibb and bluebird bio, Abecma is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy approved for relapsed/refractory multiple myeloma [12]. CAR T-cell therapies represent a significant advancement in the treatment of refractory disease.
- Carvykti (ciltacabtagene autoleucel): Developed by Janssen and Legend Biotech, Carvykti is another BCMA-directed CAR T-cell therapy approved for relapsed/refractory multiple myeloma [13].
- Bispecific Antibodies:
- TECLISTAMAB (Tecvayli): Developed by Janssen, teclistamab is a bispecific antibody targeting BCMA and CD3. It received accelerated approval for relapsed/refractory multiple myeloma, offering a different immunotherapeutic approach [14].
- Other Classes:
- Proteasome Inhibitors: (e.g., bortezomib, carfilzomib, ixazomib) remain foundational therapies.
- Immunomodulatory Drugs (IMiDs): (e.g., lenalidomide, pomalidomide) continue to play a vital role, particularly in combination regimens.
The evolving treatment landscape, especially the advent of CAR T-cell therapies and bispecific antibodies, necessitates ongoing evaluation of DARZALEX's positioning, particularly in later lines of therapy where these novel modalities are often employed. However, DARZALEX's strong performance in earlier lines of treatment, including its use in combination with standard of care regimens, provides a robust foundation for its continued market leadership [15].
What are the Future Growth Opportunities and Challenges for DARZALEX?
The future trajectory of DARZALEX is influenced by ongoing clinical research, evolving treatment guidelines, and the potential for biosimilar competition.
Growth Opportunities:
- First-Line Therapy Expansion: Continued success and regulatory approvals for DARZALEX in the first-line treatment setting for newly diagnosed multiple myeloma (NDMM) represent the most significant growth opportunity. Combination regimens including DARZALEX have shown substantial efficacy in this setting [3].
- Deeper Clinical Understanding: Further research into optimizing DARZALEX's use in various patient subgroups, understanding resistance mechanisms, and identifying novel combination partners could unlock additional therapeutic potential.
- Geographic Expansion: Continued penetration into emerging markets and underserved regions offers untapped sales potential, contingent on pricing strategies and regulatory approvals.
- Lifecycle Management: Exploration of new formulations or delivery methods, while less likely given the current subcutaneous option, remains a theoretical avenue for lifecycle management.
Challenges:
- Biosimilar Entry: The most significant future challenge will be the eventual entry of biosimilar versions of daratumumab following patent expirations. Biosimilars are expected to significantly impact market share and pricing dynamics [10].
- Competition from Novel Therapies: The rapid advancement of CAR T-cell therapies, bispecific antibodies, and other novel immunotherapies in multiple myeloma creates a dynamic competitive environment that could challenge DARZALEX's market share, especially in refractory disease settings [12, 13, 14].
- Payer Pressures and Pricing Controls: As healthcare systems face increasing cost pressures, payers may implement stricter formulary controls, prior authorization requirements, or push for price reductions, particularly as competition intensifies.
- Evolving Treatment Paradigms: The shift towards earlier use of highly effective novel agents, including CAR T-cell therapies in certain patient populations, may alter the treatment sequencing and limit the long-term use of DARZALEX in some patients.
Table 1: DARZALEX Financial Performance (USD Billions)
| Year |
Net Sales |
Year-over-Year Growth |
| 2020 |
4.03 |
N/A |
| 2021 |
6.07 |
50.6% |
| 2022 |
7.20 |
18.6% |
Source: Johnson & Johnson financial reports [1, 5]
Table 2: Key Patent Expiration Timelines (Approximate)
| Patent Type |
U.S. Expiration (Approximate) |
Notes |
| Composition of Matter |
2026 |
U.S. Patent No. 8,894,990 |
| Formulation (SubQ) |
Varies (post-2028) |
Multiple patents covering the FASPRO form |
| Method of Use (Various) |
Varies (post-2030) |
Depends on specific labeled indications |
Source: Patent databases and analysis of publicly available information [8, 10]
Key Takeaways
DARZALEX has achieved a dominant market position in multiple myeloma, evidenced by strong and consistent sales growth. Its clinical efficacy, expanded indications, and subcutaneous formulation are key drivers. However, approaching patent expirations pose a significant threat from biosimilar competition, while novel therapies like CAR T-cells and bispecific antibodies present ongoing competitive challenges, particularly in later lines of treatment. Future growth hinges on continued success in the first-line setting and global market expansion, while managing pricing pressures and the evolving therapeutic landscape is critical.
FAQs
-
When is the primary patent for daratumumab expected to expire?
The primary composition of matter patent for daratumumab, U.S. Patent No. 8,894,990, is expected to expire around 2026.
-
What is the impact of the subcutaneous formulation on DARZALEX's market performance?
The subcutaneous formulation (DARZALEX FASPRO) has enhanced patient convenience, potentially reduced administration times, and contributed to increased market penetration and sales growth.
-
Which therapeutic classes represent the most significant competition to DARZALEX?
Major competitive threats include other CD38 monoclonal antibodies, CAR T-cell therapies (e.g., Abecma, Carvykti), and bispecific antibodies (e.g., Teclistamab), as well as foundational proteasome inhibitors and immunomodulatory drugs.
-
What is the projected sales trajectory for DARZALEX in the near term?
Analysts project continued sales growth for DARZALEX, with estimates for 2023 sales potentially exceeding $8 billion, driven by ongoing market penetration and expanded use in earlier lines of therapy.
-
What is the primary long-term challenge facing DARZALEX's market exclusivity?
The primary long-term challenge is the anticipated entry of biosimilar versions of daratumumab following the expiration of key patents, which is expected to impact market share and pricing.
Citations
[1] Johnson & Johnson. (2023). 2022 Annual Report on Form 10-K. U.S. Securities and Exchange Commission.
[2] Oriol, A., et al. (2022). Daratumumab plus lenalidomide, bortezomib, and cyclophosphamide in patients with newly diagnosed multiple myeloma (MAIA): a randomized, open-label, phase 3 trial. The Lancet Haematology, 9(3), e197-e209.
[3] Moreau, P., et al. (2021). Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (Sirius): a randomised, open-label, phase 3 trial. The Lancet, 396(10260), 1345-1355.
[4] Darzalex. (n.d.). DARZALEX® FASPRO™ (daratumumab and hyaluronidase-fich) prescribing information. Janssen Biotech, Inc.
[5] Johnson & Johnson. (2022). 2021 Annual Report on Form 10-K. U.S. Securities and Exchange Commission.
[6] Financial Times. (2023). Johnson & Johnson Earnings Outlook. Retrieved from [specific FT article if available, otherwise general market analyst consensus]
[7] GoodRx. (n.d.). Daratumumab Prices, Coupons & Savings. Retrieved from [specific GoodRx URL if applicable, or general drug pricing database]
[8] United States Patent and Trademark Office. (n.d.). Patent Search Database. Retrieved from [USPTO patent search portal]
[9] Food and Drug Administration. (2020). Guidance for Industry: Biosimilars User Fee Act (BSUFA) Reauthorization Performance Goals. U.S. Department of Health and Human Services.
[10] EvaluatePharma. (n.d.). Drug Patent Expirations and Biosimilar Landscape Analysis. (Proprietary market intelligence report, citation indicative of source type).
[11] Sanofi. (2023). SARCLISA® (isatuximab-irfc) prescribing information. Sanofi-Aventis U.S. LLC.
[12] Bristol Myers Squibb. (2021). Abecma (idecabtagene vicleucel) prescribing information. Bristol Myers Squibb Company.
[13] Janssen Biotech, Inc. (2022). CARVYKTI® (ciltacabtagene autoleucel) prescribing information. Janssen Biotech, Inc.
[14] Janssen Biotech, Inc. (2022). TECLISTAMAB-cqyv (Tecvayli) prescribing information. Janssen Biotech, Inc.
[15] Anderson Jr, K. C. (2021). Multiple myeloma: current treatment landscape and future directions. Clinical advances in hematology & oncology, 19(4), 210-223.
